(Q28078225)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27669277%20AND%20SRC:MED&resulttype=core&format=json

24 March 2020

1 reference

4 references

27 October 2020

19 November 2020

4 February 2021

The Use of Exenatide in Managing Markers of Cardiovascular Risk in Patients with Type 2 Diabetes: A Systematic Review (English)

2 references

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27669277%20AND%20SRC:MED&resulttype=core&format=json

24 March 2020

main subject

cardiovascular disease

9 references

13 March 2019

14 March 2019

24 March 2019

19 June 2019

17 June 2019

18 October 2019

20 November 2019

27 October 2020

19 November 2020

4 references

18 October 2019

20 November 2019

27 October 2020

19 November 2020

fluids and secretions

1 reference

18 October 2019

1 reference

20 November 2019

anti-diabetic medication

1 reference

27 October 2020

1 reference

19 November 2020

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27669277%20AND%20SRC:MED&resulttype=core&format=json

24 March 2020

author name string

Omorogieva Ojo

series ordinal

1

1 reference

language of work or name

1 reference

23 September 2016

12 references

13 March 2019

14 March 2019

24 March 2019

19 June 2019

17 June 2019

18 October 2019

20 November 2019

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27669277%20AND%20SRC:MED&resulttype=core&format=json

24 March 2020

27 October 2020

19 November 2020

4 February 2021

International Journal of Environmental Research and Public Health

12 references

13 March 2019

14 March 2019

24 March 2019

19 June 2019

17 June 2019

18 October 2019

20 November 2019

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27669277%20AND%20SRC:MED&resulttype=core&format=json

24 March 2020

27 October 2020

19 November 2020

4 February 2021

13

2 references

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27669277%20AND%20SRC:MED&resulttype=core&format=json

24 March 2020

issue

10

2 references

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27669277%20AND%20SRC:MED&resulttype=core&format=json

Creative Commons Attribution

24 March 2020

copyright license

10 references

13 March 2019

14 March 2019

24 March 2019

19 June 2019

17 June 2019

18 October 2019

20 November 2019

27 October 2020

19 November 2020

4 February 2021

0 references

on focus list of Wikimedia project

ScienceSource

0 references

cites work

Cardiovascular effects of glucagon-like peptide 1 (GLP-1) receptor agonists

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5086680

Medical management of hyperglycemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy: a consensus statement of the American Diabetes Association and the European Association for the Study of Diabetes

20 March 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5086680

Cardiovascular safety of exenatide BID: an integrated analysis from controlled clinical trials in participants with type 2 diabetes

20 March 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5086680

Cardiovascular safety for once-weekly dulaglutide in type 2 diabetes: a pre-specified meta-analysis of prospectively adjudicated cardiovascular events

20 March 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5086680

Long-term changes in cardiovascular risk markers during administration of exenatide twice daily or glimepiride: results from the European exenatide study

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5086680

The impact of diabetes mellitus and corresponding HbA1c levels on the future risks of cardiovascular disease and mortality: a representative cohort study in Taiwan

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5086680

Improved glycemic control and reduced bodyweight with exenatide: A double-blind, randomized, phase 3 study in Japanese patients with suboptimally controlled type 2 diabetes over 24 weeks

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5086680

Exenatide twice daily: a review of its use in the management of patients with type 2 diabetes mellitus

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5086680

Changes in body weight and blood pressure: paradoxical outcome events in overweight and obese subjects with cardiovascular disease

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5086680

Determinants of vascular function in patients with type 2 diabetes

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5086680

Glycated haemoglobin and the risk of cardiovascular disease, diabetes and all-cause mortality in the Copenhagen City Heart Study

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5086680

Long-acting glucagon-like peptide 1 receptor agonists: a review of their efficacy and tolerability

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5086680

Glucagon-like peptide-1-based therapies and cardiovascular disease: looking beyond glycaemic control.

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5086680

Effects of exenatide combined with lifestyle modification in patients with type 2 diabetes

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5086680

Effect of exenatide on heart rate and blood pressure in subjects with type 2 diabetes mellitus: a double-blind, placebo-controlled, randomized pilot study

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5086680

Effects of glucagon-like peptide-1 and long-acting analogues on cardiovascular and metabolic function

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5086680

How to write a systematic review

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5086680

Baseline factors associated with glycemic control and weight loss when exenatide twice daily is added to optimized insulin glargine in patients with type 2 diabetes

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5086680

Exenatide twice daily versus premixed insulin aspart 70/30 in metformin-treated patients with type 2 diabetes: a randomized 26-week study on glycemic control and hypoglycemia

2 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5086680

A placebo-controlled trial of exenatide twice-daily added to thiazolidinediones alone or in combination with metformin

2 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5086680

Effects of exenatide (exendin-4) on glycemic control and weight over 30 weeks in metformin-treated patients with type 2 diabetes

2 June 2018

1 reference

https://api.crossref.org/works/10.3390%2FIJERPH13100941

Effects of exenatide (exendin-4) on glycemic control over 30 weeks in patients with type 2 diabetes treated with metformin and a sulfonylurea

21 January 2018

1 reference

https://api.crossref.org/works/10.3390%2FIJERPH13100941

Effects of fasting blood glucose levels and blood pressure and treatment of diabetes and hypertension on the incidence of cardiovascular disease: a study of 740 patients with incident Type 2 diabetes with up to 30 years' follow-up.

21 January 2018

1 reference

https://api.crossref.org/works/10.3390%2FIJERPH13100941

Long-term effects of exenatide therapy over 82 weeks on glycaemic control and weight in over-weight metformin-treated patients with type 2 diabetes mellitus.

21 January 2018

1 reference

https://api.crossref.org/works/10.3390%2FIJERPH13100941

The effect of chronic twice daily exenatide treatment on β-cell function in new onset type 2 diabetes.

21 January 2018

1 reference

https://api.crossref.org/works/10.3390%2FIJERPH13100941

Effects of exenatide and metformin in combination on some adipocytokine levels: a comparison with metformin monotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.3390%2FIJERPH13100941

Glycated haemoglobin and cardiovascular outcomes in people with Type 2 diabetes: a large prospective cohort study

21 January 2018

1 reference

https://api.crossref.org/works/10.3390%2FIJERPH13100941

Interim analysis of the effects of exenatide treatment on A1C, weight and cardiovascular risk factors over 82 weeks in 314 overweight patients with type 2 diabetes.

21 January 2018

1 reference

https://api.crossref.org/works/10.3390%2FIJERPH13100941

Use of Twice-Daily Exenatide in Basal Insulin–Treated Patients With Type 2 Diabetes

21 January 2018

1 reference

https://pubmed.ncbi.nlm.nih.gov/27669277

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Exenatide twice daily versus glimepiride for prevention of glycaemic deterioration in patients with type 2 diabetes with metformin failure (EUREXA): an open-label, randomised controlled trial

1 reference

https://pubmed.ncbi.nlm.nih.gov/27669277

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Identifiers

DOI

10.3390/IJERPH13100941

2 references

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27669277%20AND%20SRC:MED&resulttype=core&format=json

24 March 2020

1 reference

2 references

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27669277%20AND%20SRC:MED&resulttype=core&format=json

24 March 2020

2 references